Atlantic Union Bankshares Corp Has $20.70 Million Stock Position in Thermo Fisher Scientific Inc. $TMO

Atlantic Union Bankshares Corp increased its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 5.5% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 42,679 shares of the medical research company’s stock after acquiring an additional 2,240 shares during the period. Atlantic Union Bankshares Corp’s holdings in Thermo Fisher Scientific were worth $20,700,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Financial Management Network Inc. grew its position in Thermo Fisher Scientific by 3.7% in the 3rd quarter. Financial Management Network Inc. now owns 511 shares of the medical research company’s stock worth $248,000 after purchasing an additional 18 shares in the last quarter. Bruce G. Allen Investments LLC boosted its stake in shares of Thermo Fisher Scientific by 8.8% in the 3rd quarter. Bruce G. Allen Investments LLC now owns 236 shares of the medical research company’s stock worth $114,000 after buying an additional 19 shares during the last quarter. Revolve Wealth Partners LLC increased its position in shares of Thermo Fisher Scientific by 4.2% during the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after acquiring an additional 20 shares during the last quarter. Elevation Wealth Partners LLC lifted its holdings in Thermo Fisher Scientific by 35.1% during the third quarter. Elevation Wealth Partners LLC now owns 77 shares of the medical research company’s stock worth $37,000 after acquiring an additional 20 shares during the period. Finally, S.A. Mason LLC boosted its position in Thermo Fisher Scientific by 7.0% in the third quarter. S.A. Mason LLC now owns 319 shares of the medical research company’s stock worth $155,000 after purchasing an additional 21 shares during the last quarter. 89.23% of the stock is owned by institutional investors.

Insider Activity

In related news, VP Lisa P. Britt sold 10,225 shares of the company’s stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $571.62, for a total transaction of $5,844,814.50. Following the sale, the vice president owned 14,145 shares of the company’s stock, valued at approximately $8,085,564.90. This represents a 41.96% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Frederick M. Lowery sold 6,913 shares of the firm’s stock in a transaction on Monday, December 1st. The shares were sold at an average price of $597.68, for a total transaction of $4,131,761.84. Following the completion of the transaction, the executive vice president directly owned 14,367 shares of the company’s stock, valued at approximately $8,586,868.56. The trade was a 32.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 124,517 shares of company stock worth $72,363,568 in the last three months. Insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Trading Down 2.4%

NYSE:TMO opened at $578.20 on Monday. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $643.99. The stock’s fifty day moving average price is $593.96 and its two-hundred day moving average price is $538.75. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.89 and a quick ratio of 1.53. The company has a market cap of $217.24 billion, a P/E ratio of 32.59, a P/E/G ratio of 3.82 and a beta of 0.93.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Thursday, January 29th. The medical research company reported $6.57 earnings per share for the quarter, beating the consensus estimate of $6.45 by $0.12. The company had revenue of $12.22 billion during the quarter, compared to analysts’ expectations of $11.95 billion. Thermo Fisher Scientific had a return on equity of 16.92% and a net margin of 15.05%.The firm’s quarterly revenue was up 7.2% compared to the same quarter last year. During the same period in the previous year, the business earned $6.10 earnings per share. As a group, analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific declared that its Board of Directors has approved a stock buyback program on Thursday, November 6th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical research company to reacquire up to 2.4% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s management believes its shares are undervalued.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, January 15th. Stockholders of record on Monday, December 15th were given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date was Monday, December 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 9.70%.

Analyst Ratings Changes

A number of equities research analysts have recently commented on TMO shares. Stifel Nicolaus lifted their target price on Thermo Fisher Scientific from $583.00 to $700.00 and gave the stock a “buy” rating in a research note on Friday, January 9th. Evercore ISI reaffirmed an “outperform” rating and issued a $650.00 price objective on shares of Thermo Fisher Scientific in a research report on Monday, January 5th. The Goldman Sachs Group began coverage on shares of Thermo Fisher Scientific in a research report on Tuesday, December 9th. They set a “buy” rating and a $685.00 target price for the company. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Thermo Fisher Scientific in a research note on Thursday, October 23rd. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Thermo Fisher Scientific in a research note on Friday, January 9th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $633.68.

Key Thermo Fisher Scientific News

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Q4 results beat expectations — Adjusted EPS $6.57 and revenue $12.21B (≈+7% YoY), driven by life-sciences tools and pharma demand; the print supports near-term organic growth narrative. Read More.
• Positive Sentiment: Analyst support remains — several firms reiterated buys/positive views and one bullish write-up called the pullback a buying opportunity, highlighting resilient margins and competitive positioning. Read More.
• Neutral Sentiment: 2026 guidance set in a narrow band — FY26 revenue guide $46.3B–$47.2B and EPS $24.22–$24.80, roughly around consensus but slightly below EPS midpoint; guidance implies modest 3%–4% organic growth and stabilizing demand. Read More.
• Negative Sentiment: Market reaction focused on cautious profit outlook and margin pressure — despite the beat, investors sold into the print due to conservative margin commentary and a guidance range that doesn’t accelerate growth significantly. Read More.
• Negative Sentiment: Analyst price-target trim — TD Cowen lowered its PT from $696 to $683 while keeping a Buy rating, signaling slightly reduced upside expectations even as coverage stays positive. Read More.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.